Compare Natera Inc. Common Stock (NTRA) vs Quantumscape Corp (QS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Quantumscape Corp — how do they compare? Natera Inc. Common Stock trades at $394 (market cap $57.03B), while Quantumscape Corp trades at $3.93 (market cap $2.55B). The key difference: Natera Inc. Common Stock is far larger — about 22.4× Quantumscape Corp's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Quantumscape Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Quantumscape Corp for 37 Days on average.
| NTRA | QS | |
|---|---|---|
Market Cap | $57.03B | $2.55B |
Volume | 1,131,157 | 12,145,789 |
Sector | Health | Consumer Cyclical |
52-Week High | $425.64 | $18.44 |
52-Week Low | $179.42 | $3.93 |
Typical Hold Time | 0 Days | 37 Days |
Enterprise Value | $56.18B | $1.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
QuantumScape (QS) trades at $3.93, down 7.96% today, reflecting ongoing investor skepticism about its path to commercialization. The company remains pre-revenue with significant losses (-$435.05M net income in 2025) and negative profitability metrics (ROE -39.08%). Technical indicators show a bearish trend with oversold RSI readings, while analyst consensus leans heavily toward Hold (72.73%) with a $10.35 price target suggesting potential upside if execution improves.
QS faces substantial execution risk with commercialization delayed until at least 2029 and intense competition in solid-state batteries. The stock offers high-risk speculative potential for investors betting on breakthrough technology adoption, but requires patience through years of cash burn and dependency on future manufacturing success with partners like Volkswagen.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Quantumscape Corp
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.
Read more on QS →
